CBD novel food safety concerns are reshaping European markets. Regulators across the continent have moved to restrict cannabidiol food products, and the scientific picture underpinning those decisions is more troubling than the industry has been willing to admit. The colourful shelves of CBD wellness shops lining the streets of Paris, Rome and Athens may soon look a great deal emptier.

France fired the most dramatic opening shot. In May 2025, Paris imposed a strict ban on CBD edibles, advising consumers not to purchase or consume such products “regardless of the source.” Greece followed within days, banning retail sales of raw cannabis flowers. Italy had already introduced similar restrictions the previous year. What is unfolding across the continent is not a wave of moral panic but a belated regulatory reckoning. It centres on a landmark 2022 statement from the European Food Safety Authority (EFSA) concluding, plainly and firmly, that CBD as a novel food “cannot currently be established” as safe.

What EFSA Actually Found About CBD Novel Food Safety

EFSA’s Panel on Nutrition, Novel Foods and Food Allergens spent years reviewing the scientific literature on CBD. The Panel found not reassurance but a catalogue of data gaps serious enough to block any authorisation. By April 2022, with 19 CBD applications under active assessment, the Panel published a public statement setting out exactly what was, and was not, known.

The core problem is that virtually all human evidence on CBD comes from studies of Epidyolex. This is a prescription medicine authorised in the EU for rare childhood epilepsies, tested at doses far above anything a consumer would take in a CBD gummy or oil. In medical settings, doctors weigh adverse effects against therapeutic benefit. That trade-off does not apply to food. EFSA’s statement made clear that when assessing a novel food, regulators must establish safety on its own terms, with no benefit to offset harm.

No Observed Adverse Effect Level (NOAEL) could be identified from the available studies. The NOAEL is the benchmark reference point every food safety assessment requires. Without it, there is no reliable basis for setting a safe daily intake, and without that, there is no basis for authorisation.

Liver Damage: The Most Documented CBD Food Safety Risk

Of all the CBD food safety concerns EFSA identified, liver toxicity carries the most consistent and alarming body of evidence. Animal studies across rats, mice, dogs and rhesus monkeys showed increases in absolute and relative liver weights alongside elevated liver enzymes including ALT, AST, ALP, GGT and bilirubin. The lowest recorded LOAEL in animal data was just 10 mg per kilogram of body weight per day, from a 39-week dog study using highly purified CBD.

The human data are no less troubling. In a controlled trial of 16 healthy adults taking roughly 20 mg per kilogram of body weight per day of Epidyolex for 27 days, seven of the 16 participants showed ALT levels above the upper limit of normal. Five of those seven recorded increases more than five times above that threshold. All elevations appeared within two to four weeks. A separate trial of healthcare workers taking just 300 mg of CBD daily (roughly 4.3 mg per kilogram of body weight) found elevated liver enzymes in 6.8% of participants, prompting treatment discontinuation in one case.

Across multiple randomised controlled trials in epilepsy patients, liver enzyme elevations appeared at every dose level tested, with a clear dose-response relationship. These were not marginal signals. They were consistent, reproduced across populations, and present even at doses a supplement user might reach.

Drug Interactions: What CBD Food Consumers Are Not Being Told

The liver processes CBD through cytochrome P450 enzymes, the same enzyme family that handles a wide range of commonly prescribed drugs. EFSA’s review found that CBD inhibits several key CYP isoforms including CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A. That inhibition creates meaningful pharmacokinetic interaction risks for anyone taking medications sharing those pathways.

In one clinical study, CBD co-administration raised plasma concentrations of clobazam, an antiepileptic drug, by an average of 60%, while the drug’s active metabolite norclobazam rose by three to five times. Researchers also recorded similar interactions with tacrolimus, an immunosuppressant used after organ transplants, as well as topiramate, rufinamide and several other neurological drugs. CBD nearly doubled caffeine’s half-life in a separate pharmacokinetic study.

For someone taking a CBD supplement alongside a blood thinner, antidepressant or thyroid medication, the consequences could be serious. Grey market CBD products carry none of the warnings a pharmacist would provide.

Reproductive and Endocrine Concerns

EFSA’s panel highlighted significant animal evidence of reproductive toxicity from CBD exposure. Studies in male rodents and primates documented reductions in testicular weight, impaired spermatogenesis, decreased sperm quality and reduced fertility rates at doses starting from around 15 to 30 mg per kilogram of body weight per day. In one series of studies, neonatal CBD exposure produced lasting fertility reductions in male offspring once they reached adulthood.

Developmental toxicity studies in rats using highly purified Epidyolex produced complete litter loss for two of 20 females at 250 mg per kilogram of body weight per day. Researchers also found foetal weight reductions and structural variations in rabbits. A 26-week rat study recorded dose-dependent drops in thyroxine and rises in thyroid-stimulating hormone in male animals, alongside thyroid weight changes and follicular cell hypertrophy.

The European Medicines Agency reviewed the same Epidyolex data and concluded that post-authorisation monitoring for hormonal disturbances was necessary even for the prescription drug. Those signals carry considerably greater weight when the intended product is a food ingredient with no therapeutic justification and a far broader consumer base.

A Grey Market That Was Never Legitimate

The CBD food industry grew in full knowledge that its products had never cleared novel food authorisation. Under EU Regulation 2015/2283, foods not widely consumed in the EU before 15 May 1997 require a formal safety assessment before going to market. The EU Court of Justice confirmed in 2020 that CBD falls within that category. By March 2022, the European Commission had received over 150 novel food applications for CBD products. Not one has been approved.

Countries including France chose not to enforce the rules rigorously for years, allowing a grey market to take root. France’s CBD lobby now plans a legal challenge against the ban, arguing that hemp has been consumed as food in Europe for thousands of years and therefore should not qualify as a novel food. Regulators are unlikely to be persuaded. EFSA’s mandate is not to assess historical use but to determine whether a food is safe for the full range of consumers, including children, pregnant women and people on medication. On all three counts, the evidence base for CBD food safety remains insufficient.

What Happens to the Industry Now

Jason Etcheverry, a hemp farmer in southwest France, had just launched a range of edible CBD oils when the ban came into force. He has since recalled around 15,000 bottles and pivoted the entire output to cosmetics to avoid total loss. He estimates the financial hit at a minimum of 180,000 euros. His situation reflects the real cost of a market built on regulatory goodwill that was never guaranteed.

EFSA’s position is clear. The novel food safety review process exists because knowledge gaps around a substance’s effects on the liver, the endocrine system, reproductive function and drug metabolism represent genuine, unresolved risks. Until applicants fill those gaps with robust, purpose-designed human studies that identify a reliable NOAEL, authorisation of CBD as a food ingredient or supplement in Europe will remain out of reach.

CBD remains legal in cosmetics, and hemp cultivation continues to attract EU agricultural support under the Common Agricultural Policy. But for the edibles market, the regulatory ceiling has come down.

Source: dbrecoveryresources